Identification
Instrument name
PHARNEXT
Symbol
ALPHA
ISIN code
FR0011191287
Exchange / Market
Euronext Growth
Trading location
Paris
Products family
Stocks
ICB
Biotechnology
Operation
IPO date
IPO price
EUR 10.82
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 10.82 - EUR 13.20

Company profile

Pharnext specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases. The group has a portfolio of 2 products in clinical development: PXT-3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT-864 (Alzheimer's disease treatment).

Source: Cofisem - Last Update: 30 Apr 2020
Key Executives
Chief Executive Officer David Horn Solomon
Chief Financial Officer Peter Collum
Source: Cofisem - Last Update: 16 Apr 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Income from ordinary activities 253 2,687
Operating income -20,025 -17,908 -18,156 -13,389 -8,630
Cost (net) of financial indebtedness -2,260 -2,841 -1,226 970 -1,053
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -23,309 -21,317 -20,245 -17,366 -10,994
Net income (Group share) -23,309 -21,317 -20,245 -17,366 -10,994
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 30 Apr 2020
Shareholder information
CB Lux 23.60 %
Lohas 17.00 %
Tasly 15.40 %
Flottant 9.80 %
Other shareholders 9.40 %
Founders and Associates 8.20 %
Truffle Capital 7.40 %
Battistella 3.90 %
Industriels 2.90 %
Arbevel 2.40 %
Source: Cofisem - Last Update: 13 Jun 2019